share_log

Fulcrum Therapeutics | POSASR: Post-effective amendment to an automatic shelf registration statement on Form S-3ASR or Form F-3ASR

SEC announcement ·  Mar 2, 2022 21:03
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more